Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors

Journal for Specialists in Pediatric Nursing

Volumn 14, Issue 3, 2009, Pages 183-191

  West, Lis ^a   Brunssen, Susan H ^c   Waldrop, Julee ^b  

^a Carolina Pediatric Group   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NONE

Author keywords

Antidepressants; Autism; Pervasive developmental disorder; Pharmacotherapy; Psychopharmacotherapy; Selective serotonin reuptake inhibitors

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

AUTISM; CHILD; HUMAN; INFANT; PRESCHOOL CHILD; REVIEW;

AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; SEROTONIN UPTAKE INHIBITORS;

EID: 67650915116     PISSN: 15390136     EISSN: 17446155     Source Type: Journal    
DOI: 10.1111/j.1744-6155.2009.00196.x     Document Type: Review

References (50)

1. Aman, M., Van Bourgondien, M., Wolford, P. Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34 (12 1672 1681.
2. American Psychiatric Association 1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC : Author.
3. Anderson, G., Gutknecht, L., Cohen, D., Brailly-Tabard, S., Cohen, J., Ferrari, P., et al. (2002). Serotonin transporter promoter variants in autism: Functional effects and relationship to platelet hyperserotonemia. Molecular Psychiatry, 7 (8 831 836.
4. Bethea, T. C. Sikich, L. (2007). Early pharmacological treatment of autism: A rationale for developmental treatment. Biologic Psychiatry, 61, 521 537. (Pubitemid 46185342)
5. Buitelaar, J. Willemsen-Swinkles, S. (2000). Medication treatment in subjects with autistic spectrum disorders. European Child and Adolescent Psychiatry, 9 (5 85 97.
6. Chugani, D. C. (2002). Role of altered brain serotonin mechanisms in autism. Molecular Psychiatry, 7 (Suppl 2 S16 S17.
7. Chugani, D. C. (2005). Pharmacologic intervention in autism: Targeting critical periods of brain development. Clinical Neuropsychiatry, 2, 346 353.
8. Chugani, D., Muzik, O., Behen, M., Rothermel, R., Janisse, J., Lee, J., et al. (1999). Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Annals of Neurology, 45 (3 287 295. (Pubitemid 29120032)
9. Couturier, J. Nicolson, R. (2002). A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 12 (3 243 248. (Pubitemid 35191351)
10. DeLong, G., Ritch, C. Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44 (10 652 659. (Pubitemid 35230025)
11. DeLong, G., Teague, L. Kamran, M. (1998). Effects of fluoxetine treatment in young children with idiopathic autism. Developmental Medicine and Child Neurology, 40 (8 551 562. (Pubitemid 28401249)
12. Food and Drug Administration 2006). FDA approves the first drug to treat irritability associated with autism, Risperdal. FDA News. Retrieved December 30, 2006, from: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01485.html
13. Frazer, A. Hensler, J. (1999). Serotonin. In G. J. Siegel, B. W. Agranoff, R. W. Albers, S. K. Fisher M. D. Uhler (Eds. Basic neurochemistry: Molecular, cellular, and medical aspects (6th ed., pp. 263 292). Philadelphia : Lippincott-Raven Publishers.
14. Fukuda, T., Sugie, H., Ito, M. Sugie, Y. (2001). Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No oO Hattatsu, 33 (4 314 318 Japanese Azizian, A. (2004). Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. Journal of Autism and Developmental Disorders, 34 (4 379 393. (Pubitemid 32634472)
15. Gadow, K., Sprafkin, J. Nolan, E. (2001). DSM-IV symptoms in community and clinic preschool children. Journal of the American Academy of Child and Adolescent Psychiatry, 40 (12 1383 1392. (Pubitemid 34250957)
16. Giannotti, F., Cortesi, F., Cerquiglini, A. Bernabei, P. (2006). An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. Journal of Autism and Developmental Disorders, 36 (6 741 752. (Pubitemid 44284978)
17. Green, J., Gilchrist, A., Burton, D. Cox, A. (2000). Social and psychiatric functioning in adolescents with Asperger's syndrome compared with conduct disorder. Journal of Autism and Developmental Disorders, 30 (4 279 293. (Pubitemid 30749572)
18. Gringras, P. (2000). Practical paediatric psychopharmacological prescribing in autism: The potential and the pitfalls. Autism, 4 (3 229 247. (Pubitemid 30642607)
19. Henry, C., Steingard, R., Venter, J., Guptill, J., Halpern, E. Bauman, M. (2006). Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: A chart review. Journal of Child and Adolescent Psychopharmacology, 16 (1/2 187 195.
20. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30 (3 582 589. (Pubitemid 40271160)
21. Kim, J., Szatmari, P., Bryson, S., Streiner, D. Wilson, F. (2000). The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. Autism, 4 (2 117 132. (Pubitemid 30330576)
22. Kolevzon, A., Mathewson, K. Hollander, E. (2006). Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability. Journal of Clinical Psychiatry, 67 (3 407 414.
23. Langworthy-Lam, K., Aman, M. Van Bourgondien, M. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12 (4 311 321. (Pubitemid 36169283)
24. Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C-H., et al. (2008). TrkB regulates neurogenesis and governs sensitivity to antidepressive treatment. Neuron, 59, 399 412.
25. Martin, A., Koenig, K., Anderson, G. Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33 (1 77 85. (Pubitemid 36323142)
26. McDougle, C., Kresch, L. Posey, D. (2000). Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders, 30 (5 427 435. (Pubitemid 30845751)
27. Moore, M., Eichner, S. Jones, J. (2004). Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy, 38 (9 1515 1519. (Pubitemid 39100208)
28. Muhle, R., Trentacoste, S. Rapin, I. (2004). The genetics of autism. Pediatrics, 113 (5 472 486.
29. Murphy, D.L., Lerner, A., Rudnick, G. Lesch, K-P. (2004). Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Molecular Interventions, 4 (2 109 123. (Pubitemid 38584973)
30. Namerow, L., Thomas, P., Bostic, J., Prince, J. Monuteaux, M. (2003). Use of citalopram in pervasive developmental disorders. Developmental and Behavioral Pediatrics, 24 (2 104 108. (Pubitemid 36546777)
31. Owley, T., Walton, L., Salt, J., Guter, S., Winnega, M., Leventhal, B., et al. (2005). An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44 (4 343 348. (Pubitemid 40393272)
32. Palmen, S., van Engeland, H., Hof, P. Schmitz, C. (2004). Neuropathological findings in autism. Brain: A Journal of Neurology, 127 (12 2572 2583. (Pubitemid 39627367)
33. Posey, D., Erickson, C., Stigler, K. McDougle, C. (2006). The use of serotonin reuptake inhibitors in autism and related disorders. Journal of Child and Adolescent Psychopharmacology, 16 (1/2 181 186.
34. Posey, D., Litwiller, M., Koburn, A. McDougle, C. (1999). Paroxetine in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 28 (2 111 112.
35. Posey, D., Puntney, J., Sasher, T., Kem, D. McDougle, C. (2004). Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. Journal of Child and Adolescent Psychopharmacology, 14 (2 233 241. (Pubitemid 38988789)
36. Potenza, M., McDougle, C. (1997). The role of serotonin in ASD. CNS Spectrums, 2, 25 42.
37. Reinhold, J., Molloy, C. Manning-Courtney, P. (2005). Electrocephalogram abnormalities in children with autism spectrum disorders. Journal of Neuroscience Nursing, 37 (3 136 138.
38. Scahill, L., Chappell, P., Kim, Y., Schultz, R., Katsovich, L., Shepherd, E., et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention-deficit hyperactivity disorder. American Journal of Psychiatry, 158 (7 1067 1074. (Pubitemid 32623110)
39. Schwartz, J. (1995). Neurotransmitters. In E. R. Kandel, J. H. Schwartz T. M. Jessell (Eds.). Essentials of neural science and behavior (pp. 293 306). Stanford, CT : Appleton & Lange.
40. Sikich, L., Hickok, J. Todd, R. (1990). 5-HT1A receptors control neurite branching during development. Developmental Brain Research, 56, 269 274. (Pubitemid 20364138)
41. Steingard, R., Zimnitzky, B., DeMaso, D., Bauman, M. Bucci, J. (1997). Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7 (1 9 15. (Pubitemid 27252846)
42. Stetler, C. B. (2001). Updating the Stetler Model of research utilization to facilitate evidence-based practice. Nursing Outlook, 49 (6 272 279. (Pubitemid 33602068)
43. Sugie, Y., Sugie, H., Fukuda T., Ito, M., Sasada, Y., Nakabayashi, M., et al. (2005). Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism Development Disorders, 35 (3 377 385. (Pubitemid 41125975)
44. Sugie, Y., Sugie H., Fukuda, T., Ito, M. Ohzeki, T. (2003a). Studies on the adverse effects of fluvoxamine treatment in children with autistic disorder: Correlation with genetic polymorphism in serotonin related genes. No To Hattatsu, 35 (3 233 237 Japanese H., Fukuda, T., Ito, M. Ohzeki, T. (2003b). Serotonin 2A receptor gene polymorphism and clinical efficacy of fluvoxamine in children with autistic disorder. No To Hattatsu, 35 (1 23 28 Japanese Kraus, D. (2003). Lexi-Comp's pediatric dosage handbook (10th ed.). Hudson, OH : Lexi-Comp, Inc. (Pubitemid 36554243)
45. Tsai, L. (1999). Psychopharmacology in autism. Psychosomatic Medicine, 61 (5 651 656.
46. West, L. Waldrop, J. (2006). Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatric Nursing, 32 (6 545 549.
47. West, L., Waldrop, J. Brunssen, S. (2009). Pharmacologic treatments for the core deficits and associated symptoms of autism in children. Journal of Pediatric Health Care, 23, 75 89.
48. Williams, G., Sears, L. Allard, A. (2004). Sleep problems in children with autism. Journal of Sleep and Research, 13 (3 265 268. (Pubitemid 39331187)
49. Witwer, A. Lecavalier, L. (2005). Treatment incidence and patterns in children and adolescents with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 15 (4 671 681. (Pubitemid 41434371)
50. Yokoyama, H., Hirose, M., Haginoya, K., Munakata, M. Ilnuma, K. (2002). Treatment with fluvoxamine against self-injury and aggressive behavior in autistic children. No To Hattatsu, 34 (3 249 253 Japanese. (Pubitemid 34496308)